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Summary 
Immunoglobulin G (IgG)  molecules are glycosylated in C.2 at Asn297;  the N-linked carbo- 
hydrates attached there have been shown to contribute to antibody (Ab) stability and various 
effector functions. The carbohydrate attached to the IgG constant region is a complex biantennary 
structure. Alterations in the structure of oligosaccharide have been associated with human diseases 
such as rheumatoid arthritis and osteoarthritis. To study the effects  of altered carbohydrate structure 
on Ab effector function, we have used gene transfection  techniques to produce mouse-human 
chimeric IgG1 Abs in the Chinese hamster ovary (CHO) cell line Lec 1, which is incapable of 
processing the high-mannose intermediate through the terminal glycosylation  steps. We also 
produced IgG1 Abs in Pro-5, the wild-type CHO cell line that is the parent of Lec 1. The Pro- 
5-produced Ab (IgGl-Pro-5) was similar to IgG1-My 1, a myeloma-produced IgG1 Ab of the 
same specificity, in its biologic properties  such as serum half-life, ability to effect complement- 
mediated cytolysis, and affinity for FcylLI. Although the Lec 1-produced Ab, IgG1-Lec 1, was 
properly assembled and retained antigen specificity, it was incapable of complement-mediated 
hemolysis and was substantially deficient in complement consumption, Clq binding, and C1 
activation.  IgG1-Lec 1 also showed reduced but significant affinity for Fcq/R.1 receptors. The 
in vivo half-life of IgG1-Lec 1 was shorter than that of either the myeloma- or Pro-5-produced 
counterpart, with more being cleared during the or-phase and with more rapid clearance during 
the E-phase. Clearance of IgG1-Lec 1 could be inhibited by the administration of yeast-derived 
mannan. Thus the uptake of IgG1-Lec 1 appears to be accelerated by the presence of terminally 
mannosylated oligosaccharide. Therefore, certain Ab functions as well as the in vivo fate of the 
protein are dramatically affected by altered carbohydrate structure.  Expression of Igs in cell lines 
with defined glycosylation mutations is shown to be a useful technique for investigating  the 
contribution of carbohydrate structure to Ab function. 
1Abs are glycoproteins  and are glycosylated at charac- 
teristic positions  according to their isotype. The IgG 
molecule has one conserved glycosylation  site, at Asn297, 
within the C.2 domain of each of its two heavy chains. The 
oligosaccharides attached there are accommodated  within the 
internal space between the two C,2  domains (1)  and are 
thought to stabilize the molecule and to contribute to the 
tertiary structure of the Fc (2). Aglycosylated IgGs have been 
shown to be deficient in such effector functions as comple- 
ment activation, Fc receptor recognition, and Ab-dependent 
cell-mediated cytotoxicity (ADCC)  1 (3-5). 
The oligosaccharides associated with the C.2 of IgG are 
a Abbreviations used in this paper: ADCC, Ab-dependent  cell-mediated 
cytotoxicity;  CHO, Chinese  hamster  ovary;  DNS, dansyl;  Endo  H, Endo- 
glycosidase  H; GeI-HBS, Hepes-buffered  saline. 
complex biantennary structures  whose core structure con- 
sists of two ot-mannosyl structures attached to a/~-mannosyl- 
di-N-acetylchitobiose  unit (see Fig. 1 A). The composition 
of the outer arms varies  with the degree of terminal processing 
and considerable heterogeneity of carbohydrate structures is 
observed. This heterogeneity has been observed both in the 
IgG component of normal human serum (6, 7) as well as 
in IgG paraproteins (8). Whereas heterogeneity is always  seen, 
the relative concentration of  different carbohydrate structures 
is altered in some diseases. Among individuals with rheuma- 
toid arthritis,  the proportion of agalactosylated IgG sugars 
is increased,  both in serum and synovial  fluid (9, 10). Fc agalac- 
tosylation  has also been observed in patients  with chronic 
juvenile arthritis,  Crohn's disease, and tuberculosis (11, 12). 
In some clinical studies, the degree of agalactosylation cor- 
related with disease activity in rheumatoid arthritis patients 
(13). It has been proposed that the presence of agalactosylated 
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Figure  1.  (A) Schematic repre- 
sentation of the complex bianten- 
nary  structure  characteristic  of 
C.2-assodated oligosaccharide (7). 
The core  residues are shown  in plain 
type, and  the  terminal residues, 
whose variable  addition confers het- 
erogeneity upon the structure, are 
italicized  and  highlighted with 
(+/-) symbols. (B) The truncated 
oligosaccharide produced by the 
CHO glycosylation  mutant Lec 1 
is shown (16). 
carbohydrate causes conformational changes that result in aber- 
rant  activity in the Ig,  such as increased tendency for self- 
aggregation. 
It is therefore of interest to obtain populations of Abs with 
defined alterations in carbohydrate structure so that the con- 
tributions of specific oligosaccharide residues to glycoprotein 
function can be assessed. Sequential exoglycosidase digestion 
of glycoprotein hormones  such as choriogonadotropin  has 
shown that successive removal of the outer sugars results in 
decreased biologic activity (14). Agalactosylated IgG prepared 
by glycosidase digestion showed decreased complement acti- 
vation and Fc receptor binding activity (15). However, enzy- 
matic or chemical treatment may damage the protein back- 
bone. Therefore, in this study Igs were produced in Chinese 
hamster  ovary  (CHO)  cells  that  have  defined  defects  in 
oligosaccharide processing. Numerous mutants have been de- 
rived by selection for lectin resistance and mostly possess single 
glycosylation defects (16). These mutations occur at distinct 
steps in the oligosaccharide biosynthesis pathway, resulting 
in the accumulation of intermediate structures with reduced 
overall carbohydrate heterogeneity.  In previous studies (17) 
glycosylation mutants transfected with choriogonadotropin 
genes produced proteins that were deficient in signal trans- 
duction. 
CHO cells are widely used as recipient cells for the produc- 
tion  of recombinant  proteins.  In particular,  several studies 
have documented the production and characterization of Igs 
produced in CHO cells. When compared to their lymphoid 
cell-produced counterparts,  these Abs were found to retain 
Ag specificity and affinity (18-20), as well as effector func- 
tions such as complement- and cell-mediated cytotoxicity (21) 
and Fc receptor recognition (22). Thus it was reasonable to 
assume that Igs produced in wild-type CHO cells are func- 
tionally  equivalent  to  those in  myeloma cells  and  that  Ig 
production in the CHO glycosylation mutants would permit 
the study of the specific  effects of altered glycosylation on 
otherwise normal proteins. 
In the present studies chimeric mouse-human  IgG1 Abs 
were produced in Lec 1, a CHO cell line deficient in N-ace- 
tylglucosaminyltransferase I activity (23). Lec 1 synthesizes 
oligomannosyl structures which are truncated sugars not nor- 
mally found on IgG (see Fig.  1 B). The resulting Abs were 
assembled and secreted correctly, but were shown to be al- 
tered in their biologic properties and significantly deficient 
in numerous effector functions. Chimeric IgG1 Abs were also 
produced in Pro-5, the wild-type CHO parent of Lec 1. As 
expected, the biologic properties of these Abs were similar 
to their  myeloma-produced counterparts. 
Materials  and Methods 
Cell Lines.  The CHO cell lines cell lines Lec I and Pro-5 were 
obtained from the American Type Culture Collection (Rockville, 
MD), having been deposited by Dr. Pamela Stanley (Albert Ein- 
stein College of Medicine, New York, NY) (23). The original cell 
lines and transfectants were maintained at 37~  under  5% COg 
in IMDM (Irvine Scientific, Santa Ana, CA) supplemented with 
5% FCS (Hydone Laboratories, Logan, UT). The cells were main- 
tained as monolayers on tissue culture-treated  petri dishes (Falcon 
Labware, Lincoln Park, N3). 
The transfectoma cell line TPRI.3 (3; for clarity, referred to in 
this paper as IgG1-My 1, the myeloma-produced chimeric IgG1) 
was produced by transfecting the Ig nonproducing mouse myeloma 
cell line P3X63Ag8.653 with chimeric heavy and light chain genes 
with murine variable  regions from the anti-dansyl (DNS) hybridoma 
27-44 and human 3/1 and g constant regions. Cells were maintained 
in IMDM supplemented with 5% iron-supplemented calf serum 
(Hydone). 
The human monocyte-like  cell line U937, which expresses  Fc~RI 
and Fc3'RII receptors, was maintained  in RPMI  1640 medium 
(GIBCO BRL, Gaithersburg, MD) supplemented with 10% FCS. 
Vector Design for Transfection of CHO Cells.  The heavy and light 
chain constructs used to produce DNS-specific IgG1 chimeric Abs 
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in nonlymphoid cells by replacing the Ig-specific promoter and en- 
hancer with the SV40 promoter and enhancer. To construct the 
heavy chain vector, the 2.1-kb-BamHI fragment containing  the 
leader and  Ig promoter was subcloned into  the BamHI site  of 
pBR322. Complete digestion with EcoRI and partial digestion with 
HindlII removed the Ig promoter but retained the leader sequence. 
The SV40 promoter/enhancer was obtained from the pSV2gpt ex- 
pression vector, where it is flanked by PvulI and HindlII restric- 
tion sites. The PvulI site at the 5' end of the SV40 promoter was 
converted to an EcoRI restriction site by linker tailing.  The EcoRI- 
HindlII fragment containing the SV40 promoter/enhancer was then 
cloned into the homologous restriction sites 5' of the anti-DNS 
leader sequence.  The BamHI-SalI fragment, which contains the 
V, gene and the J-C intron, was then cloned into the BamHI and 
SalI sites of this pBK322 derivative, so that it adjoined the pro- 
moter/leader sequence. The heavy chain enhancer, which is flanked 
by two XbaI restriction sites in theJ-C intron, was deleted by XbaI 
digestion and religation. The EcoRI-SalI fragment was then joined 
to human IgG1 in the expression vector pSV2AHgpt (see Fig. 2 
A). Nucleotide sequencing of the vector showed that no muta- 
tions had been introduced in the heavy chain coding region during 
vector construction. 
To construct the light chain vector, a PvulI site 5' of the leader 
sequence but 3' of the light chain promoter was converted to a 
HindlII site by linker tailing.  The EcoRI-HindlII fragment en- 
coding the SV40 promoter/enhancer was joined to the V~ at that 
site. The intronic K enhancer was deleted by EcoRI digestion and 
religation.  The resulting light chain expression vector lacks Ig- 
specific controlling elements but instead contains the SV40 pro- 
moter and enhancer (see Fig. 2 B). Large scale plasmid purification 
was performed for both  the  expression vectors with  a plasmid 
purification kit  (Qiagen,  Chatsworth,  CA). 
Transfection of CHO Cells by Lipofection.  The Lec 1 and Pro-5 
cells were each grown to 50-75% confluence on three tissue cul- 
ture--treated 60  x  15-mm petri dishes. For either recipient cell line, 
the dishes were rinsed three times with serum-free IMDM before 
transfection. 30/zg each of the heavy and light chain expression 
vectors were combined and diluted in sterile water to a final volume 
of 200 #1 in a polystyrene tube. 90/zl of Lipofectin (Bethesda Re- 
search Laboratories, Bethesda, MD) was then added, the contents 
mixed, and the tube allowed to stand at room temperature for 15 
min. The mixture was then diluted to a final volume of 9 ml with 
serum-free IMDM. To each dish of Lec 1 or Pro-5 cells three ml 
of the Lipofectin mixture was added dropwise, with the drops dis- 
tributed over the surface of the plate. The plates were incubated 
overnight at 37~  in a humidified 5% CO2 incubator. The next 
day, an equal volume of IMDM with 10% FCS was added to each 
dish. On the following day, each plate was trypsinized and the cells 
diluted in 24 ml selection medium (IMDM supplemented with 10% 
FCS,  1%  Nystatin  [GIBCO BRL],  1% gentamicin and  1 mM 
histidinol [Sigma Chemical Co., St. Louis, MO]) and distributed 
100 #l/well into 96-well flat-bottomed microtiter plates (Coming, 
Inc., Corning, NY). Fresh selection medium was added 3 d later. 
Colonies were generally seen within  10 d. 
Transfectants were screened for Ab production by an ELISA using 
microtiter plates (Immulon 2; Dynatech Laboratories, Inc., Chan- 
tilly,  VA) coated with DNS-BSA or goat anti-human IgG. The 
detecting Ab was alkaline phosphatase-conjugated goat anti-human 
x light chain (Sigma Chemical Co.). Positive clones were expanded 
and subcloned. 
Biosynthetic Labeling and Endoglycosidase  H Hydrolysis.  Secreted 
Abs were obtained from [3SS]methionine-labeled transfectants.  Ap- 
pvtJi Ec ~RI ~ndl/IH  ~  bal 
~gpt  C,  jp~  SaIl 
~  BstEII 
BamHI 
j 
FCO  e~,AAnnl 
I  EcoRI 
V L  Hindlll 
Figure  2.  Vectors  for the expression of Ig genes using SV40 control- 
ling elements. The SV40 early promoter and enhancer are shown on the 
heavy chain (.4) and light chain (B) vectors by a darkly cross-hatched ar- 
rowhead, and the murine leader and variable region genes by dark boxes. 
Murine intronic sequences are indicated by a thin black line. Human con- 
stant region exons are shown by diagonally striped boxes and the inter- 
vening sequences by striped black lines. The pSV2-derived sequences are 
represented by failed lines, with the prokaryotic selectable marker (Amp) 
and the eukaryotic selectable markers (gpt and h/s) shown by stippled and 
lightly shaded arrows, respectively.  Arrows indicate the direction of tran- 
scription. Restriction sites discussed in the text are shown. 
proximately 3  x  106 cells were trypsinized, washed in methionine- 
free DME (Irvine Scientific),  and resuspended in the same medium 
supplemented with 15 #Ci [3SS]methionine  (Amersham, Arling- 
ton Heights, IL) and 400 #g/ml proline, and incubated at 37~ 
for 3 h. The supernatants were harvested and the Ab immunopre- 
cipitated  with  a  mixture  of rabbit  anti-human  Fc  and  rabbit 
anti-human Fab antisera (both prepared by Letitia A. Wims in this 
laboratory) followed by precipitation with Staphylococcus  aureus pro- 
tein A (IgG Sorb; The Enzyme Center, Boston, MA) and washing. 
The Abs were resuspended in sample buffer (25 mM Tris, pH 6.7, 
2% SDS, 10% glycerol, and 0.008% bromophenol blue) and eluted 
from protein A by boiling.  The samples were analyzed by SDS- 
PAGE  and autoradiography. 
For Endoglycosidase H  (Endo H) hydrolysis,  35S-labeled super- 
natants were treated with 50 mM sodium citrate (pH 5.5), 100 mM 
2-ME (Eastman Kodak Co., Rochester, NY), 2 mM PMSF (Sigma 
Chemical Co.), and 0.005 U Endo H (Boehringer Mannheim, In- 
dianapolis,  IN) in a final vol of 1 ml. After incubation for 24 h 
at  37~  the  reactions  were  terminated  by  the  addition  of 5 
1089  Wright and Morrison /~lAample 2 M Tris, pH 8.0. The samples were then spun briefly 
in a microcentrifuge to pellet debris and Ab was immunoprecipi- 
tated as described. The samples were analysed by SDS-PAGE using 
Tris-glycine gels. 
Protein Purification.  Purified Ab for biological characterization 
was obtained by a~nity chromatography as previously described 
(24).  Transfectoma cells were grown in roller bottle cultures in 
IMDM plus 2% c~-calf serum (Hyclone). Supernatants from satu- 
rated cultures were buffered with 10 mM phosphate buffer (0.43  M 
Na2PO4,  0.57  M  Na2HPO4)  and  supplemented  with  0.45  M 
NaC1, 0.02 M EDTA, and 0.02% NAN3. Supernatants were sterile 
filtered, degassed, and passed through AH-Sepharose columns to 
which the DNS isomer 2-dimethyl-aminonaphthalene-5 sulfonyl 
chloride had been coupled (Molecular Probes, Inc., Eugene, OR). 
Ab was eluted with a second DNS isomer, N-(5-carboxy-pentyl)- 
2-dimethyl-aminonaphthyl-5-sulfonamide. The bound hapten was 
removed by extensive dialysis  against Tris-buffered saline  (TBS). 
The concentration of purified protein was determined with the bi- 
cinchoninic  acid (BCA) protein assay (Pierce,  Rockford,  IL). 
Measurement of Ag Affinity.  A competitive binding assay was 
used to compare the affinity for DNS of the chimeric Abs. Im- 
mulon 2 microtiter plates were coated overnight at 4~  with DNS- 
BSA (5/~g/ml diluted in PBS, 50 #l/well) and blocked with 3% 
BSA. The murine DNS-specific Ab 27-44 was diluted to 200 ng/ml 
in BBS/1%  BSA and mixed in equal vol with serial dilutions of 
IgG1-My 1, IgG1-Pro-5, or IgG1-Lec 1. The dilutions ranged from 
0 to 24 #g/ml. The mixtures of murine and chimeric anti-DNSs 
were added in duplicate (50/zl/well) to the DNS-coated plate and 
incubated overnight at 4~  Bound 27-44 Ab was detected by in- 
cubation with an alkaline phosphatase-conjugated goat anti-mouse 
ic Ab (Zymed Laboratories, Inc., S. San Francisco,  CA), followed 
by the addition of substrate (p-nitrophenyl phosphate disodium, 
obtained from Sigma Chemical Co.). The data were plotted to com- 
pare the percentage of maximal binding (in the absence of compet- 
itor) to the amount of competitor present, and the point at which 
50% inhibition of Ag binding by 27-44 occurred was determined. 
As a negative control,  a chimeric dextran-specific IgG1 Ab was 
diluted and incubated in similar fashion with 27-44. 
Measurement of Complement Fixation.  The capacity of Abs for 
complement fixation was measured by several methods. In the di- 
rect assay, SRBC (Pocono Rabbit Farm, Canadensis, PA) were coated 
with DNS-BSA by the chromic chloride coupling procedure (25). 
The  Ag-coated  SRBC  were  loaded  with  SlCr, washed,  and 
brought to a 2% suspension in Hepes-buffered saline with 0.1% 
gelatin (Gel-HBS). Ab at various concentrations, 0-20/zg/ml and 
diluted in the same buffer, was added in duplicate 50-/zl aliquots 
to  round-bottomed  microtiter  plates  that  were  kept  on  ice 
throughout preparation. Chromium-loaded SRBC were added (50 
/zl), followed by 25/zl guinea pig complement (C'; Colorado Serum 
Co., Denver, CO) that had been preabsorbed with DNS-coated 
SRBC and adjusted to 10 LU/25 #1.  Controls included  sponta- 
neous lysis (SRBC in Gel-HBS alone), total lysis (SRBC in water), 
SRBC incubated with Ab but without complement, and SRBC 
with  complement and buffer alone.  Experimental samples were 
plated in duplicate, and controls in quadruplicate. The plates were 
then covered and incubated in a 37~  water bath for 45 min. The 
plates were spun at 800 rpm in a countertop centrifuge (Beckman 
Instruments Inc., Fullerton, CA) to pellet red cells and debris and 
50 #1 from each well was withdrawn  and counted in a gamma 
counter (model Gamma 5500;  Beckman Instruments Inc.).  Per- 
cent lysis was calculated as:  100  x  [(mean experimental cpm  - 
mean cpm SRBC lysis in the presence of complement alone)/(total 
lysis  -  spontaneous lysis)]. 
For the complement consumption assay (25) Ab (8/zg/25/zl) 
was incubated in duplicate with increasing amounts of DNS-BSA 
(0-5/zg/well) and 2 CHs0 U of guinea pig complement in round- 
bottomed  microtiter  plates  for 45  min  at  37~  [SlCr]-loaded 
hemolysin-sensitized SRBC were then added and incubation was 
continued for another 45 min. The plates were centrifuged as be- 
fore  and  the  amount  of SlCr  release  measured  with  a  gamma 
counter. The percentage of complement consumption was calcu- 
lated as  100  x  [1-(cpm of Ab  +  Ag  +  C'/cpm Ab  +  C')]. 
Clq Binding Assay.  A  solid phase assay was used to measure 
the capacity of Abs to bind Clq, the first step in the complement 
cascade (26).  Immulon 2 microtiter plates were coated with 100 
#l/well of DNS-BSA diluted to 10/zg/ml in PBS. The plates were 
then blocked with PBS plus 3% BSA overnight at 4~  and washed. 
The DNS-specific Abs were diluted serially from a stock concen- 
tration of 10 #g/ml in PBS plus 1% BSA, were added in duplicate 
100 #l/well, and incubated overnight at 4~  After washing with 
HBS, 100/zl 0.125%  normal human serum diluted in HBS was 
added to each well and the plates were incubated at 37~  for 2 h. 
HBS was used for washing and as the diluent at this point because 
phosphate inactivates complement. Goat anti-human Clq was then 
diluted 1:10,000 in PBS plus 1% BSA and incubated at room tem- 
perature for 2 h, after which the plates were washed and incubated 
at room temperature for 2 h more with alkaline phosphatase-con- 
jugated swine and anti-goat IgG (Boehringer Mannheim). After 
a final washing with PBS, substrate was added and the plates were 
read at 410 nm on a plate reader (model MR 700; Dynatech). IgG4, 
which does not bind Clq, was included on each plate as a negative 
control. 
Fc Receptor Binding.  Purified Abs (10-20/zg)  were iodinated 
using  Iodobeads  (Pierce).  1251 was  obtained  from  ICN  (Irvine, 
CA).  Before the assay, U937 cells were harvested, washed with 
PBS, and resuspended in fresh RPMI supplemented with 10% FCS 
and 100 U/ml recombinant human IFN-'y (the gift of Dr. Jorge 
Gavilondo-Cowley,  Centro de Ingenieria Genetica y Biotecnologica, 
La Habana, Cuba). After a 48-h incubation, the cells were washed 
and incubated in serum-free DMEM at 37~  for 2 h to dissociate 
any serum Ig that might be bound to the Fc receptors. The cells 
were then washed again and resuspended to 5  x  106 cells/ml in 
assay buffer (Hepes buffer; 0.1 M  Hepes, pH 7.4, 0.12 M  NaC1, 
0.005 M KC1, 0.0012 M MgSO4, 0.015 M  HAc, 0.01 M glucose, 
and  1%  BSA). 
The radiolabeled Ab diluted in assay buffer to ,,o 10 ng/50 #1 
was mixed in 0.6 ml Eppendorf tubes with increasing amounts 
of the homologous unlabeled Ab in the same volume. Threefold 
dilutions  from a  100-fold  excess of unlabeled Ab were tested in 
duplicate. To measure nonspecific binding, a 1,000-fold  excess of 
commercial human IgG (Miles Inc., Kankakee,  IL) was used as in- 
hibitor. 400 #1 of stimulated U937 cells were added to each tube, 
and the tubes were rotated on a Labquake rotator (Labindustries, 
Inc., Berkeley,  CA) at 18~  for 2.5 h. The tubes were then spun 
briefly in a microfuge, the supernatants  were withdrawn, and 100 #1 
was measured in a gamma counter. The pellets were washed three 
times with PBS and the supernatant carefully removed by aspira- 
tion. Each tube was then placed in the gamma counter to measure 
the radioactivity retained by the pellets. Scatchard analysis was ap- 
plied to determine the binding constants and number of receptors 
per cell  (27). 
In Vivo Half-Life.  Female BALB/c mice were fed for at least 
1 wk with water treated with potassium iodide (3 drops of 10 mg/ml 
per 100 ml water). For each 12SI-labeled protein, three mice were 
injected intraperitoneally with 106 cpm labeled  Ah (28).  Whole- 
body radioactivity was measured with a scaler/ratemeter (model 
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crystal  large enough to accommodate  a mouse. Measurements  com- 
menced at 3 rain after injection and continued at regular intervals 
for 300 h. The percentage of radioactive  counts remaining in each 
sample (background subtracted) was: 100  x  [(cpm from each 
sample)/(cpm observed immediately after injection)]. To calculate 
the half-life  of  each protein, the percentage  of  radioactivity  remaining 
was plotted against the intervals at which cpm were measured. 
In further experiments, mice were injected intravenously with 
the IgG1-Lec 1 prepared as described previously, but were coin- 
jected with either 10 mg mannan (purified  yeast  polysaccharide  from 
Saccharomyces cerevisiae, purchased from Sigma, and dissolved to 
10 mg/100/zl PBS) or the equivalent vol of PBS (29). After 1 h, 
the mannan-injected mice were given a second intravenous injec- 
tion of 10 mg mannan. The mice were monitored for whole-body 
radioactivity as before, and clearance  of radioactivity over time was 
plotted as described. 
Results 
Chimeric mouse-human mAbs provide useful tools for the 
study of Ig function. In previous studies, the human IgG1 
constant region joined to the murine DNS-specific  variable 
region expressed in murine myeloma cells was used to inves- 
tigate the functional properties of the resulting protein (30, 
31).  In  the  current  study,  by  substituting  the  Ig-specific 
promoters and enhancers with those of SV40,  the same Ab 
has been produced in Pro-5, a wild-type CHO cell line, and 
Lec 1, a variant of Pro-5 deficient in N-acetylglucosaminyl- 
transferase  I activity. The Ab expressed  in Lec 1 will have 
a high-mannose carbohydrate of a type that is not normally 
seen on IgG attached to C.2 in place  of the normal com- 
plex carbohydrate. Thus it is possible without clinical or en- 
zymatic modification to obtain large quantities of purified 
Ab with a defined, altered carbohydrate structure. 
The CHO cells were refractory to electroporation, but 
efficient  transfection was attained by lipofection. Transfec- 
tants selected for resistance to 1 mM histidinol were obtained 
from both Pro-5 and Lec 1. The transfectants fully assembled 
H2L2 molecules at a level "5/zg/ml of Ab/106  cells/24 h, 
sufficient to produce adequate amounts of purified Ab from 
roller bottle culture. One clone of each, IgG1-Pro-5  and IgG1- 
Lec 1,  was chosen for further study. 
To confirm that carbohydrate with altered structure was 
present on the Lec 1-produced Ab, the Lec I transfectant and 
myeloma cells producing a chimeric Ab of the same isotype 
were biosynthetically  labeled and the supernatants from each 
were treated with Endo H, which hydrolyzes high-mannose 
and hybrid but not complex oligosaccharides.  Hydrolysis was 
conducted under reducing conditions to expose the sugar to 
the enzyme and the proteins were immunoprecipitated and 
analyzed by SDS-PAGE. The myeloma-produced IgG, IgG1- 
My 1, is mostly unaffected by treatment with Endo H  al- 
though a small amount of enzyme hydrolysis is observed (Fig. 
3). In contrast, the Lec 1-produced IgG, lgG1-Lec 1, is sen- 
sitive to Endo H  and the heavy chain of the treated protein 
shows a faster mobility than the untreated one. Furthermore, 
the heavy chain of untreated IgG1-Lec 1 shows faster migra- 
tion than does that of untreated IgG1-My 1, consistent with 
Figure  3.  Endo  H hydrolysis 
of transfectoma  proteins. Transfec- 
toma proteins were subjected to 
hydrolysis with Endo H under 
reducing  conditions  and were  ana- 
lyzed by SDS-PAGE. Heavy  and 
light chains are indicated. 
the presence of a truncated carbohydrate on IgG1-Lec 1. The 
identity of the band migrating between the heavy and light 
chains is not clear, but it appears to be a CHO cell-specific 
product that is not glycosylated. 
To  evaluate  the  biologic  activity of these  Abs  in  Ag- 
dependent assays it was necessary to confirm that the Abs' 
affinity for Ag is equivalent. The IgG1-Lec  1, IgG1-Pro-5, 
and IgG1-My I Abs were tested in competition experiments 
for their ability to inhibit Ag binding by the murine anti- 
DNS 27-44  with identical variable  regions (Fig. 4).  With 
all the chimeric Abs,  50%  inhibition of binding by 27-44 
was attained at a concentration of '~3/xg/ml. The inhibi- 
tion curves of these Abs are very similar overall,  thus their 
Ag binding capacity should be equivalent at the Ab concen- 
trations employed in the various functional assays. 
Previous work from this laboratory and others (3-5) had 
shown that the presence of carbohydrate in the C.2 region 
of IgG1 is essential for Fc-associated functions such as com- 
plement activation and Fc receptor binding. The IgG1-Lec 
1 protein containing a carbohydrate with altered structure, 
as well as the Pro-5-produced Ab,  were now compared to 
the biologically active  IgG1-My 1 Ab produced in murine 
myeloma cells. 
The ability of the IgG1 Abs to activate complement was 
determined using several assays  designed to investigate different 
aspects of the complement cascade. In the direct assay, which 
determines the ability of the Ab to complete the comple- 
ment cascade and effect hemolysis, increasing amounts of Ab 
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Figure 4.  Competition  of IgG1-My  1, IgGl-Pro-5,  and IgG1-Lec  I with 
the binding of murine anti-DNS 27-44 to Ag, as determined  by EL1SA. 
The data are plotted as percentage  of maximum  binding in the absence 
of  competing  Ab, against  the increasing  amount  of  competitor.  The nega- 
tive control is a chimeric lgG1 Ab specific for dextran. 
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Ag-coated SRBC. As shown in Fig. 5 A, red cell lysis in- 
creased as the amount of IgG1-My 1 or IgG1-Pro-5 was in- 
creased to a maximal lysis of "~  In contrast, IgG1-Lec 
1 failed to mediate lysis at any of the concentrations tested. 
In the complement comsumption assay, the capacity of Ab 
to deplete the complement components is measured. A con- 
stant amount of Ab is first incubated  with complement in 
the presence of increasing amounts of Ag; if the Ag-Ab com- 
plexes consume any of the complement components, they 
will not be available to lyse the hemolysin-coated indicator 
cells. Decreased lysis therefore indicates an increase in com- 
plement activation.  The ability of the IgG1-My 1, as well 
as IgG1-Pro-5 Ab, to consume complement is Ag depen- 
dent with total consumption ranging from of 0.5 to 50/zg 
Ag/well (Fig. 5 B). In contrast, IgG1-Lec 1 consumes only 
a low level of complement (<15%) in an Ag-independent 
manner. 
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Figure  5.  Complement activation  by IgG1 chimeric Abs. (A) Direct 
lysis of SlCr-loaded, DNS/BSA-coated SRBC. Cells were incubated with 
complement and increasing  amounts of Ab (in duplicate)  for 45 min at 
37~  Supernatants were then harvested and the amount of lysis was quan- 
titated with a gamma counter as described.  The percent  lysis is plotted 
against the Ab concentration.  (B) Complement consumption.  Ab (8 #g/25 
#1) was incubated  with complement and with increasing amounts of Ag 
at 37~  for 45 rain. SRBC were sensitized with hemolysin,  loaded with 
slCr, and added to the reaction for a further incubation  of 45 rain.  Com- 
plement consumption was calculated from chromium release as described. 
To determine whether the defect in complement activa- 
tion by IgG1-Lec 1 lies in the initial steps of the complement 
cascade, we compared the ability of these Abs to bind Clq, 
the first step in the activation of the classical complement 
pathway. Because Clq binds poorly to monomeric IgG,  a 
solid-phase assay was used in which Ag-Ab complexes are 
formed on a plastic surface at sufficient density to allow Clq 
binding, which is then quantitated by Clq specific  antiserum. 
An IgG4 Ab, which does not bind Clq, was included as a 
negative control. Both IgG1-My 1 and IgG1-Pro-5  bound 
Clq well, the IgG4 Ab, as expected, did not bind, and IgG1- 
Lec 1 showed significant but reduced Clq binding capacity 
(Fig. 6). 
Fc Receptor Binding.  To determine the affinity of binding 
of the IgG to the Fc3,R.I present on IFN-y-stimulated U937 
cells, a constant amount of radiolabeled Ab was incubated 
with increasing amounts of unlabeled homologous ligand and 
the amount of radioactivity  bound determined. Values for 
the dissociation constant and numbers of receptors per cell 
were obtained  through Scatchard analysis; a representative 
experiment is shown in Fig. 7. U937 cells stimulated with 
IFN-3' displayed ,,o4.2  x  104 receptors per cell. The mean 
Ka of IgG1-My 1 was 1.79 x  10 -9 M -1, in agreement with 
previously published values (31). The Kd of IgG1-Pro-5 was 
very similar, at  1.55  x  10 -9 M -2.  The Kd of IgG1-Lec 1 
was reduced approximately four- to sixfold, with a mean value 
of 8.2  ￿  10 -9 M -1. Thus, the ability of the mannosylated 
IgG1-Lec 1 to bind Fcq'RI is slightly reduced but still sub- 
stantial. 
In Vivo Half-life.  To determine the in vivo half-life of the 
molecules,  t2SI-labeled Abs  were introduced into BALB/c 
mice by intraperitoneal  injection,  and the amount of radio- 
activity present  in each mouse determined by whole-body 
counting. The half-life values obtained by this method have 
been found to correlate well with those obtained by intrave- 
nous injection of labeled Abs and counting of  blood samples 
(28). IgG1-My 1 was cleared in the 3-phase with a half-life 
of 6.3 d (Fig. 8). In this experiment, virtually all of the IgG1- 
My 1 was cleared in the 3-phase, but in other experiments, 
0.4 
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0.2 
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.01 
Figure  6. 
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Clq binding by DNS-specific Abs. Binding was measured 
by ELISA as described using Ag-coated microtiter plates. An IgG4 Ab, 
which does not bind Clq, was included  as a negative control. 
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Figure 7.  Scatchard analysis of the binding of IgG1-My 1 (e), IgG1-Pro- 
5 (O), and IgG1-Lec 1 ([:3) to U937 cells. The U937 cells had been stimu- 
lated  for 48 h  with 100 U/ml IFN-3' to increase expression of Fc3,R1 
receptors. A constant amount of t2SI-labeled  Ab was incubated with U937 
cells with increasing amounts of unlabeled homologous competitor, and 
the amount of radioactivity bound to pelleted and washed cells was mea- 
sured with a gamma counter.  The line represents a least squares fit of the 
data  and was calculated using Excel. 
up to 40%  of the protein was cleared in the oL-phase. Ap- 
proximately 40% of the IgG1-Pro-5 Ab was rapidly cleared 
in the o~-phase; the remaining Ab had a B-phase half-life of 
5.7 d, very similar to that of IgG1-My 1. In contrast, over 
80%  of IgG1-Lec 1 is consistently cleared rapidly whereas 
the remaining protein has a greatly reduced in vivo half-life 
of 4 d. Thus the IgG produced in the myeloma and Pro-5 
CHO cells persists in the circulation considerably longer than 
does its mannosylated counterpart. 
To investigate whether the rapid clearance  of IgG-Lec 1 
100 
I  ~~, IgG1-My  1 
o  ,gG,-P~-51  IgG1  -Lec I 
'~  10 
L~ 
1 
0  100  200  300  400 
Time  (hours) 
Figure  8.  In vivo half-life  of IgG1-My 1, IgGl-Pro-5, and IgG1-Lec 
1 Abs. BALB/c  mice were injected  intraperitoneaUy  with 12SI-labded  Ab 
and the persistence  of radioactivity  was measured  by whole-body  counting 
and is displayed  as a percentage of injected dose over time. The B-phase 
half-life was determined from the values obtained after 48 h. 
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Figure 9.  Effect  of mannan  on the in vivo  clearance  of IgG1-Lec  1. Mice 
were given  intravenous  injections  of radiolabeled  protein, either concur- 
rently  with 10 mg mannan or without. The mice  receiving  mannan  were 
given a second  injection I h later; the times  of mannan injection  are indi- 
cated  by arrows along  the x-axis. The percentage  of radioactivity  remaining 
was measured over time; the initial measurement  was taken  immediately 
after injection. 
was  mediated through mannose receptors  on cells  in  the 
reticuloendothelial system, mice injected intravenously (tail 
vein) with 12sI-IgG1-Lec 1 were concurrently injected with 
either 10 mg of yeast mannan or with an equal volume of 
PBS. 1 h after injection, those mice receiving mannan were 
given a second injection of 10 mg mannan, and all mice were 
monitored by whole-body counting for 24 h. As shown in 
Fig. 9, the control mice injected with PBS demonstrated con- 
tinuous and rapid loss of radioactivity. In contrast, the mannan- 
injected mice retained virtually all radioactivity for over 8 h, 
after which rapid clearing abruptly ensued. This result sug- 
gests that clearance takes place using the mannose receptors 
and these were blockaded temporarily by the yeast polysac- 
charide.  By 24 h, the level of remaining radioactivity was 
the same in all the mice. 
Discussion 
The presence  of carbohydrate in C.2 is essential  for bio- 
logical activity of IgG. Although the carbohydrate attached 
there is heterogeneous, a considerable body of  evidence shows 
that certain glycosylation  patterns can contribute to aberrant 
Ig activity. Previous studies (15) had indicated that IgG ren- 
dered deficient in galactose by glycosidase treatment is deficient 
in Clq and Fc receptor binding. However, to rule out any 
diminution of Ab function that might be a consequence of 
the conditions of enzyme treatment, it would be desirable 
to produce biosynthetically Abs with defined alterations in 
carbohydrate structure and to determine their functional prop- 
erties. 
Proteins with altered carbohydrate structures can be pro- 
duced in well-characterized glycosylation mutants of CHO 
cells (32). Wild-type CHO cells have been widely used for 
Ab production (18-22),  so the variety of available mutants 
provides  an expression  system appropriate for the study of 
specific glycosylation defects of interest. Additionally, genetic 
engineering techniques provide the means to produce homo- geneous populations  of isotypes of interest.  Therefore, we 
designed expression vectors for the production of  DNS-specific 
IgG1 Abs in CHO cells. In this initial study using this ex- 
perimental approach, the Igs were produced in wild-type CHO 
cells as well as Lec 1, a cell line incapable of processing the 
high mannose intermediate through the terminal glycosyla- 
tion steps (Fig. 1). The resulting Abs were properly assem- 
bled and secreted  and retained Ag affinity. Using this approach, 
Abs with novel oligosaccharide structures were made avail- 
able for study. 
The classical pathway of complement activation is initi- 
ated by the binding of Ab to Ag with the subsequent binding 
and activation of C1. Unlike the myeloma- or CHO-produced 
chimeric Abs, the IgG1-Lec 1 Ab was incapable of comple- 
ment-mediated  lysis of hapten-coated erythrocytes, although 
the  Lec  1-produced  Ab  did  demonstrate a  reduced  but 
significant amount of Clq binding. The Clq binding site 
on IgG defined by residues Glu318, Lys320, and Lys322 lies 
along  an  exposed  ~-strand on  C,2  (33). Other  residues 
within this region have been shown to contribute to isotypic 
differences  in complement activation capability (34). It is pos- 
sible, therefore, that a conformational  change introduced into 
the C.2 domain by the altered carbohydrate  serves to de- 
crease Clq binding. 
The level of Clq binding possessed by IgG1-Lec 1 might 
not be sufficient to activate the subsequent steps of the com- 
plement cascade. That Clq binding does not necessarily lead 
to cell lysis has been documented in studies of the compara- 
tive lyric efficiencies of different Ab isotypes (26, 35, 36). 
Additionally the IgG1-Lec 1 Ab might be an impaired sub- 
strate for interaction with complement proteins involved in 
the later stages of the complement cascade. The IgG1-Lec 
i differs from aglycosylated IgG1 which appears unable to 
bind Clq (3). 
Compared to the wild-type Ab, the Ka of IgG1-Lec 1 for 
Fc3'R1 receptors on U937 cells was reduced approximately 
four- to sixfold. Whereas the loss of carbohydrate abolishes 
Fc receptor binding, changing the oligosaccharide structure 
has demonstrable but  less drastic  effects, consistent  with 
previous reports (15, 37). Degalactosylated IgG produced by 
glycosidase treatment showed reduced IgG binding to U937 
cells, although a binding constant was not determined (15). 
Intact chimeric Abs produced in yeast were as capable of 
ADCC as the murine counterpart, but could not activate 
complement (37). The oligosaccharide produced by yeast is 
a bulky structure with 30-100 terminal mannose residues (38) 
and is quite different from the truncated structure with ter- 
minal mannose residues produced by Lec 1 cells. Residues 
on IgG critical for Fc receptor binding lie in the lower hinge 
region and in the hinge proximal region, and whereas glycosy- 
lation is required for Fc receptor binding and ADCC (39-41), 
our results suggest that the presence of a truncated carbohy- 
drate is sufficient to allow at least some Fc receptor binding. 
Additional studies are required to define precisely the carbo- 
hydrate structure necessary for different effector functions. 
The in vivo fate of the IgG1-Lec 1 in mice is drastically 
affected by the presence of a carbohydrate of altered structure 
in C,2.  Whereas in vivo persistence of aglycosylated IgG1 
was equivalent to that of wild type (3, 42), that of the man- 
nosylated Ab was reduced substantially. Moreover, 80%  of 
IgG1-Lec I was rapidly cleared in the ct phase. Comparative 
in vitro protease digestion showed that IgG1-Lec 1 was no 
more sensitive to protease than was the wild-type Ab (data 
not shown). Rather, it seemed possible that clearance  of IgG1- 
Lec 1 might occur by a different mechanism than does the 
clearance of IgG1-My 1 and IgG1-Pro-5. 
Numerous studies have described systems for glycoprotein 
clearance in the liver that are localized to different compart- 
ments and that recognize different terminal sugar residues 
(43, 44). Liver endothelial cells bear receptors that recognize 
terminal mannose residues through which rapid clearance of 
mannosylated proteins such as ricin, OVA, and the COOH- 
terminal propeptide of type I procollagen has been observed 
(43-47). Mannose receptor-mediated clearance of glycopro- 
teins occurred more rapidly than did clearance via galactose 
receptors, which were compartmentalized to liver endothelial 
and parenchymal cells, respectively (46, 47).  Since the ad- 
ministration of mannan effectively inhibited the clearance of 
IgG1-Lec 1, although with the injection protocol used the 
effect was temporary,  the Ab appears susceptible to uptake 
by mannose receptors. This result was somewhat surprising, 
since the Fc-associated  carbohydrate normally is "buried" be- 
tween the heavy chains. Indeed,  the IgG1-Lec 1 Ab failed 
to show binding to Sepharose-Con A (data not shown). How- 
ever, a report that IgG-Ag complexes injected into rats were 
rapidly cleared  from the circulation, suggested that Ag-induced 
conformational changes in IgG caused the Fc carbohydrate 
to be exposed and susceptible to clearance by the galactose 
receptors on liver parenchymal cells (48). Although DNS- 
specific Abs are unlikely to encounter Ag in vivo, a confor- 
mational change may have been triggered in some way, per- 
haps through aggregation,  exposing the mannose residues. 
By expressing Abs in CHO cells with defined mutations 
in glycosylation,  we have produced Abs with novel (and 
reasonably homogeneous) carbohydrate structures. Changing 
the structure of the carbohydrate may profoundly affect the 
behavior of Abs. In particular, the presence of a carbohydrate- 
bearing terminal mannose residues in C.2 of IgG1 abolishes 
complement activation, attenuates Fc receptor binding,  and 
profoundly shortens  the in  vivo  half-life of the protein. 
Whereas in the current study the carbohydrate present on 
the IgG differed in structure from the naturally occurring 
carbohydrate, in future studies it will be possible to produce 
Abs with carbohydrate structures  similar to those found on 
the circulating  Igs in patients  with certain diseases. Thus, 
it will be possible to determine the biologic properties  of 
these Abs. Such studies may yield insights into the relation- 
ship between Ab structure and pathogenesis. With this tech- 
nology it is possible not only to produce and study proteins 
with a wide variety of glycosylation defects but also to ana- 
lyze a "family" of proteins,  such as IgG with different iso- 
types, to see if effects are universal or are seen only with a 
particular  protein.  Studies like these not only may provide 
information about the role of carbohydrate in protein func- 
tion but may also yield insights into how changes in carbo- 
hydrate structure affect protein conformation. 
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